AFP - Sanofi withdraws anti-obesity drug in US
PARIS (AFP) — French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.
A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States.
“Sanofi-Aventis will work towards submitting the rimonabant file to the FDA at a future date,” the company said, adding that it will “undertake the necessary discussions with the FDA to determine the required modifications to its file.”
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
Blockbuster obesity drug aims to win $4bn sales for Sanofi-Aventis
Obesity drug ‘to make a splash’.(Sanofi-Aventis)
Long-Term Benefits of Rimonabant Confirmed in Two-Year Study.
The FDA’s expert panel concluded that suicidal thoughts appeared to be a side-effect of taking Acomplia, which has …
Read the full article with a Free Trial at MyWire.
